Austrade invites Australian companies with capabilities across advanced therapeutics, medtech/medical devices, AI drug discovery and R&D, CROs and related service to express interest to participate BioKorea in Korea from 27-30 April 2026.

Korea’s status as a global innovation leader is show by its number 1 ranking in Asia in 2025 Global Innovation index, and 4th overall globally. 

As the world’s 13th largest pharmaceutical market, Korea is leveraging a record approximately A$2.37 billion dollars government R&D budget in 2026. This growth will support the transition from licensing-out technologies to independently commercialising global "blockbuster" drugs. 

This creates high-value business opportunities for Australia, particularly in merging Australia’s world-class clinical trial expertise and biotech feedstock with Korea's massive biomanufacturing infrastructure and AI-driven digital health platforms. 

Celebrating over a decade of high-impact collaboration, the Australia-Korea biotechnology partnership between AusBiotech and the Korea Health Industry Development Institute (KHIDI) leverages Australia’s world-class clinical trial infrastructure alongside Korea’s advanced biomanufacturing capabilities. This mature alliance was recently reaffirmed through a renewed MOU in 2024. The partnership’s momentum continued at BioKorea 2025, where 36 leading Australian biotech companies showcased their capabilities, further solidifying Australia’s reputation as an ideal R&D partner for Korea.